Floatz logo

Therapeutic Asset Ratings

394 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pembrolizumab/Vibostolimab Coformulation
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLCP2B (57)
(+)-VINCRISTINE
Cholangiocarcinoma
Merck Sharp & Dohme LLCP2B (57)
Zilovertamab Vedotin
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLCP2B (57)
Benadryl
Ovarian Cancer
Merck Sharp & Dohme LLCP3B (56)
FLUDROCORTISONE
Metastatic Prostate Carcinoma
Merck Sharp & Dohme LLCP3B (56)
Intismeran
Melanoma
Merck Sharp & Dohme LLCP3B (56)
Sacituzumab Tirumotecan
Cervical Cancer
Merck Sharp & Dohme LLCP3B (56)
Sacituzumab Tirumotecan
Endometrial Carcinoma
Merck Sharp & Dohme LLCP3B (56)
Trastuzumab Deruxtecan
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (56)
Patritumab Deruxtecan
Breast Cancer
Merck Sharp & Dohme LLCP2B (56)
Pembrolizumab
Lymphoma
Merck Sharp & Dohme LLCP2B (56)
TAMOXIFEN
Advanced Solid Tumors
Merck Sharp & Dohme LLCP2/3B (56)
mk-3475
Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLCP3CCC (55)
mk-4830
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLCP2CCC (55)
Tucatinib
Breast Neoplasm
Merck Sharp & Dohme LLCP2CCC (55)
Calderasib
Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLCP3CCC (54)
Calderasib
Rectum Adenocarcinoma
Merck Sharp & Dohme LLCP3CCC (54)
DEXAMETHASONE
Primary Peritoneal Carcinoma
Merck Sharp & Dohme LLCP3CCC (54)
Favezelimab
Hematopoietic And Lymphoid System Neoplasm
Merck Sharp & Dohme LLCP3CCC (54)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa
Hematologic Malignancies
Merck Sharp & Dohme LLCP3CCC (54)
Ifinatamab Deruxtecan
Prostate Neoplasm
Merck Sharp & Dohme LLCP3CCC (54)
Levoleucovorin
Rectum Adenocarcinoma
Merck Sharp & Dohme LLCP3CCC (54)
Lorazepam
Prostatic Neoplasms
Merck Sharp & Dohme LLCP3CCC (54)
Sacituzumab Tirumotecan
Ovarian Cancer
Merck Sharp & Dohme LLCP3CCC (54)
Sacituzumab Tirumotecan
Ovarian Neoplasm
Merck Sharp & Dohme LLCP3CCC (54)
Showing 176 to 200 of 394 assets
PreviousPage 8 of 16Next